Plant & Quality
研究與發展Research & Development
High Barrier Generics
新聞發佈News & Media
Home > News & Media > News
Communication starts here.
TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO
TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
TWi Pharmaceuticals Launches Generic MEGACE ES® After Favorable Decision In Patent Suit
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Guanfacine HCl ER Tablet
TWi Pharmaceuticals Announced the promotion of R&D EVP Jianbo Xie as COO
TWi Announces Settlement with Takeda on Dexilant® Litigation
TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.
TWi Pharmaceuticals announces the first shipment of its generic product in the U.S. market.
TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan.
©Copyright 2013 安成國際藥業股份有限公司版權所有